News
Featured News
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
BIOVECTRA and Revolution Biomanufacturing Partner to Deliver Integrated mRNA Design and GMP Production Services — Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up
November 6, 2025
COVID-19: Our Obligation
\At BioVectra, we take our obligation as an essential service very seriously. […]
Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation
Much of the innovation occurring in the pharmaceutical industry today is achieved by smaller pharma/biotech firms with limited commercial manufacturing experience […]
<a class="btn btn-secondary
BIOVECTRA Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital
BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital […]
Mallinckrodt Agrees to Sell BIOVECTRA Inc. to H.I.G. Capital for $250 Million
Statement from BIOVECTRA President, Oliver Technow, on BIOVECTRA’s sale to H.I.G. Capital: “We are very excited to enter into this new chapter with H.I.G. Capital! […]
BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project
BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project Windsor, Nova […]
BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)
BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API) Charlottetown, Prince Edward Island, Canada (March 17, 2019) […]
